Update of minimally invasive surfactant therapy
- PMID: 29042870
- PMCID: PMC5638833
- DOI: 10.3345/kjp.2017.60.9.273
Update of minimally invasive surfactant therapy
Abstract
To date, preterm infants with respiratory distress syndrome (RDS) after birth have been managed with a combination of endotracheal intubation, surfactant instillation, and mechanical ventilation. It is now recognized that noninvasive ventilation (NIV) such as nasal continuous positive airway pressure (CPAP) in preterm infants is a reasonable alternative to elective intubation after birth. Recently, a meta-analysis of large controlled trials comparing conventional methods and nasal CPAP suggested that CPAP decreased the risk of the combined outcome of bronchopulmonary dysplasia or death. Since then, the use of NIV as primary therapy for preterm infants has increased, but when and how to give exogenous surfactant remains unclear. Overcoming this problem, minimally invasive surfactant therapy (MIST) allows spontaneously breathing neonates to remain on CPAP in the first week after birth. MIST has included administration of exogenous surfactant by intrapharyngeal instillation, nebulization, a laryngeal mask, and a thin catheter. In recent clinical trials, surfactant delivery via a thin catheter was found to reduce the need for subsequent endotracheal intubation and mechanical ventilation, and improves short-term respiratory outcomes. There is also growing evidence for MIST as an alternative to the INSURE (intubation-surfactant-extubation) procedure in spontaneously breathing preterm infants with RDS. In conclusion, MIST is gentle, safe, feasible, and effective in preterm infants, and is widely used for surfactant administration with noninvasive respiratory support by neonatologists. However, further studies are needed to resolve uncertainties in the MIST method, including infant selection, optimal surfactant dosage and administration method, and need for sedation.
Keywords: Noninvasive ventilation; Respiratory distress syndrome; Surfactant.
Conflict of interest statement
Conflicts of interest: No potential conflict of interest relevant to this article was reported.
Figures
Similar articles
-
Comparison of minimally invasive surfactant therapy with intubation surfactant administration and extubation for treating preterm infants with respiratory distress syndrome: a randomized clinical trial.Clin Exp Pediatr. 2022 Apr;65(4):188-193. doi: 10.3345/cep.2021.00297. Epub 2021 Jul 28. Clin Exp Pediatr. 2022. PMID: 34325499 Free PMC article.
-
Evidence reviews for respiratory support: Specialist neonatal respiratory care for babies born preterm: Evidence review B.London: National Institute for Health and Care Excellence (NICE); 2019 Apr. London: National Institute for Health and Care Excellence (NICE); 2019 Apr. PMID: 35157413 Free Books & Documents. Review.
-
Surfactant therapy via thin catheter in preterm infants with or at risk of respiratory distress syndrome.Cochrane Database Syst Rev. 2021 May 10;5(5):CD011672. doi: 10.1002/14651858.CD011672.pub2. Cochrane Database Syst Rev. 2021. PMID: 33970483 Free PMC article.
-
Nasal high flow therapy for primary respiratory support in preterm infants.Cochrane Database Syst Rev. 2023 May 5;5(5):CD006405. doi: 10.1002/14651858.CD006405.pub4. Cochrane Database Syst Rev. 2023. PMID: 37144837 Free PMC article. Review.
-
Minimally invasive surfactant therapy versus intubation for surfactant administration in very low birth weight infants with respiratory distress syndrome.Pediatr Neonatol. 2020 Apr;61(2):210-215. doi: 10.1016/j.pedneo.2019.11.002. Epub 2019 Nov 13. Pediatr Neonatol. 2020. PMID: 31818537
Cited by
-
Surfactant Therapy for Respiratory Distress Syndrome in High- and Ultra-High-Altitude Settings.Front Pediatr. 2022 Mar 4;10:777360. doi: 10.3389/fped.2022.777360. eCollection 2022. Front Pediatr. 2022. PMID: 35311054 Free PMC article.
-
Eliminating Risk of Intubation in Very Preterm Infants with Noninvasive Cardiorespiratory Support in the Delivery Room and Neonatal Intensive Care Unit.Biomed Res Int. 2019 Jan 13;2019:5984305. doi: 10.1155/2019/5984305. eCollection 2019. Biomed Res Int. 2019. PMID: 30733962 Free PMC article.
-
Creation of a rating scale to teach Less Invasive Surfactant Administration (LISA) in simulation.BMC Med Educ. 2024 Feb 14;24(1):146. doi: 10.1186/s12909-024-05118-6. BMC Med Educ. 2024. PMID: 38355497 Free PMC article.
-
Comparison of Minimally Invasive Surfactant Therapy and Intubation-surfactant Administration-extubation in Premature Neonates with Respiratory Distress Syndrome.Oman Med J. 2025 Mar 31;40(2):e730. doi: 10.5001/omj.2025.55. eCollection 2025 Mar. Oman Med J. 2025. PMID: 40740316 Free PMC article.
-
Comparison of minimally invasive surfactant therapy with intubation surfactant administration and extubation for treating preterm infants with respiratory distress syndrome: a randomized clinical trial.Clin Exp Pediatr. 2022 Apr;65(4):188-193. doi: 10.3345/cep.2021.00297. Epub 2021 Jul 28. Clin Exp Pediatr. 2022. PMID: 34325499 Free PMC article.
References
-
- Guttentag S, Foster CD. Update in surfactant therapy. NeoReviews. 2011;12:e625–e634.
-
- Seger N, Soll R. Animal derived surfactant extract for treatment of respiratory distress syndrome. Cochrane Database Syst Rev. 2009;(2):CD007836. - PubMed
-
- Yost CC, Soll RF. Early versus delayed selective surfactant treatment for neonatal respiratory distress syndrome. Cochrane Database Syst Rev. 2000;(2):CD001456. - PubMed
-
- Soll RF, Morley CJ. Prophylactic versus selective use of surfactant in preventing morbidity and mortality in preterm infants. Cochrane Database Syst Rev. 2001;(2):CD000510. - PubMed
-
- Iliodromiti Z, Zygouris D, Sifakis S, Pappa KI, Tsikouras P, Salakos N, et al. Acute lung injury in preterm fetuses and neonates: mechanisms and molecular pathways. J Matern Fetal Neonatal Med. 2013;26:1696–1704. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources